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ABSTRACT
Introduction: Persistent infection with sexually
transmitted, high-risk human papillomavirus (HPV)
types is the cause of all cervical cancers and some
anogenital and oropharyngeal cancers. HPV is an
extremely common asymptomatic infection but little
known and poorly understood by the public. Patients
with HPV-related cancers have new and challenging
information needs due to the complex natural history
of HPV and the stigma of sexual transmission. They
may ask questions that are outside the remit of the
traditional cancer consultation, and there is a lack of
guidance on how to counsel them. This study aims to
fulfil that need by developing and testing cancer site-
specific scripted consultations.
Methods and analysis: A synthesis of findings
generated from previous work, a systematic review of
information-based interventions for patients with HPV-
related cancers, and interviews with cancer clinicians
will provide the evidence base underpinning provisional
messages. These will be explored in three phases of
face-to-face interviews with 75–90 purposively selected
patients recruited in cancer clinics to: (1) select and
prioritise the most salient messages, (2) phrase the
messages appropriately in plain English and, (3) test
their acceptability and usefulness. Phases 1 and 2 will
draw on card-sorting methods used in website design.
In phase three, we will create cancer site-specific
versions of the script and test them using cognitive
interviewing techniques.
Ethics and dissemination: The study has received
ethical approval. Findings will be published in a peer-
reviewed journal. The final product will be cancer-
specific scripted consultations, most likely in the form
of a two-sided information sheet with the most
important messages to be conveyed in a consultation
on one side, and frequently asked questions for later
reading on the reverse. However, they will also be
appropriate and readily adaptable to web-based uses.
BACKGROUND
Nearly all sexually active men and women
are exposed to human papillomavirus (HPV)
at some stage in their lives; in most people, it
does not cause health problems. HPVs that
infect the anogenital tract fall into two broad
groups: those that cause warts (low-risk) and
those associated with cancer (high-risk).
Persistent infection with high-risk HPV types
causes all cervical cancer,1 most vulvar,
vaginal2 and anal cancer,3 approximately half
of penile cancers,4 as well as an increasing
subset of oropharyngeal cancers,5 6 and HPV
is also implicated in cancer precursor condi-
tions in the cervix, anus, vulva and vagina. In
some instances, HPV status will determine
the approach to cancer treatment.7
The rising number of HPV-related cancers
is a major public health issue. The concept
of a virus causing cancer is frightening.8
The association of cervical precancer with
HPV has clear psychosocial adverse effects.9
Strengths and limitations of this study
▪ Human papillomavirus (HPV) infection is an area
of cancer communication which is new for
patients and healthcare professionals: we
address an urgent need for timely and accurate
information.
▪ Patients will take an active role in developing
scripted consultations about HPV-related cancers
that are informative, reassuring and important to
them.
▪ The resulting scripts, developed for use in con-
sultations, will be readily modifiable for website
content and generalisable beyond UK NHS
settings.
▪ Participants will not be asked to identify their
sexual orientation; therefore, there is likely to be
some bias towards heterosexuals in the sample.
▪ Owing to the comparative rarity of penile cancer,
we will not seek to include this cancer in the
sample.
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Health professionals must be prepared to discuss HPV
status because affected patients may want to know the
cause of their condition and may question the implica-
tions for their sexual partners.10 11 Although discussions
about HPV between patients and health professionals
are becoming more common in cervical disease, patients
express concern about the stigma attached to sexual
transmission.12–14 There is little rigorous research into
how clinicians communicate with patients for the other
cancers associated with HPV.
Patients and the public know very little about HPV.
Despite the introduction of HPV vaccination in
schools, and HPV testing within cervical screening pro-
grammes in the UK and several other countries, sys-
tematic reviews demonstrate consistently poor
knowledge and lack of awareness that HPV is a sexu-
ally transmitted causative factor for cervical cancer.9 15
Furthermore, women who are found to be HPV
positive during cervical screening experience distress,
anxiety and a notable lack of understanding.9
Healthcare professionals do not know enough about
HPV-associated cancers, a developing area of research
where there are still many uncertainties and good
quality patient information is lacking; they have difﬁ-
culty initiating discussions about HPV and sexual
matters with patients, and ﬁnd it challenging to
explain HPV infection; they describe it as a ‘can of
worms’.16 Addressing stigma and psychosexual infor-
mation needs, in addition to explaining the nature
of HPV infection and the link between HPV and
cancer, requires the development of high-quality,
clear and understandable educational materials and
messages.
A ‘counselling paradigm’ has been proposed, but a
limitation of this approach is the lack of studies where
patient input has informed education and counselling
strategies.17 Scripted consultations have been used
effectively to deliver patient-sensitive, evidence-based
information about difﬁcult scientiﬁc subjects.18
Written material is designed to educate both health-
care professionals and patients, and improve health
outcomes. Our methodological approach ﬁts with the
Cochrane Consumers and Communication Review
Group’s ‘The Knowledgeable Patient’,19 a summary of
health beneﬁts from improving patient and public/
professional interactions by integrating systematic
review evidence with patient and public views, as well
as the co-production principle embedded in NHS
Wales’ ‘Prudent Healthcare’.20 We will also draw on
the resources and recommendations for producing
high-quality patient information outlined by the
Patient Information Forum.21 22 We will generate novel
ﬁndings by intentionally including patient perspectives
into a proposed strategy to provide timely and accurate
information on the role of HPV infection in cancer,
an area of cancer communication which is relatively
new for patients, the general public and many health-
care professionals.
AIMS AND OBJECTIVES
Overall aim
To develop and ﬁeld test evidence-based cancer site-
speciﬁc versions of a scripted HPV consultation, includ-
ing ‘take-home’ information for patients diagnosed with
HPV-related cancer. These scripts will contain the most
salient points not to miss, rather than verbatim wording
for a consultation. They will be in a format that is suit-
able for delivery to patients by cancer clinicians;
however, they could be readily adapted to provide
web-page content for information providers such as
NHS Choices, Cancer Research UK and Macmillan.
They will be designed to reduce anxiety and increase
HPV knowledge in patients with speciﬁc cancers.
Objectives
▸ To conduct a systematic review of information-based
interventions for patients with HPV-related cancers
▸ To conduct telephone interviews with clinicians to
identify their views about, and current practice in,
talking about HPV with their patients
▸ To develop a list of appropriate messages based on
previous work (the HPV Core Messages study), the
systematic review and the clinician interviews
▸ To conduct face-to-face exploratory interviews with
patients diagnosed with cervical, vulval, vaginal, anal
or oropharyngeal cancers to select and prioritise the
most salient messages and reﬁne the content and
phrase the messages in language that is easy to
understand
▸ To set the resulting messages in scripts that provide
take-home messages, which participants believe are
succinct, salient and address their concerns, then test
their acceptability and usefulness in cognitive debrief
interviews with patients and further reﬁne as
necessary.
RESEARCH PLAN—METHODS AND ANALYSIS
Developing evidence-based draft messages
Between 2008 and 2011, we developed informational
messages pertinent to HPV vaccination and HPV testing
in the context of cervical cancer prevention (the HPV
Core Messages study). The evidence base for these mes-
sages was derived from systematic reviews of people’s
views about HPV vaccination15 and testing,9 qualitative
interviews with vaccination-aged girls and their
parents,23 and with women in the cervical screening pro-
gramme, and UK-wide surveys of health professionals
and the public (mainly information needs). An expert
panel and systematic review of reviews underpinned the
scientiﬁc content of the messages. A subset of these mes-
sages is appropriate to be adapted for patients with a
diagnosis of HPV-related cancer and this will be our
starting point for developing a list of generic and cancer
site-speciﬁc messages. We will create a supporting evi-
dence matrix, derived from a new systematic review and
clinician interviews, and scrutinised by experts including
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specialists in virology and epithelial pathology, and
genitourinary medicine, as well as cancer specialists and
a patient representative, to ensure that the messages are
relevant and accurate.
Systematic review
We will search Medline, PsycInfo, Embase, Cinahl, Web
of Knowledge and The Cochrane Library for studies of
any design with a focus on informing patients about any
HPV-related cancer. A search strategy developed for
Medline will be adapted for the other databases (see
online supplementary ﬁle 1). Participants could be
patients or clinicians; the intervention or topic of inter-
est is information delivered in any format or medium
(eg, written leaﬂets, web pages, videos, consultations).
Two reviewers will carry out screening, study selection
and quality appraisal; disagreements will be resolved by
discussion. Study quality will be appraised using the
Critical Appraisal Skills Programme (CASP) tools appro-
priate to study type. Data, including study details,
setting, population, methods, etc, will be extracted into
predeﬁned forms. We will present the review ﬁndings in
a table, accompanied by a narrative summary description
and explanation. Any new messages, indicated by the
review ﬁndings, and their supporting evidence will be
added to the evidence matrix.
Clinician interviews
We will conduct 35–40 telephone interviews with health-
care professionals in Wales, covering all relevant clinical
roles (surgeons, oncologists and cancer nurse specialists)
and cancer sites (oropharyngeal, gynaecological, anal,
penile). We will utilise a topic guide focusing on current
practice in consultations with patients including:
whether they initiate conversations about HPV; what
factors inﬂuence the way they approach the topic; what
sort of explanations they give; what questions patients
commonly ask and what concerns they express; what
works well in conversations about HPV; what areas of
knowledge are difﬁcult to explain or have the potential
to increase patients’ concerns. Interviews will be audio
recorded and transcribed. New or unforeseen issues that
arise during the interviews may be added to the topic
guide and further explored in succeeding interviews. We
will read the transcripts to familiarise ourselves with the
data, which will then be analysed using framework-based
synthesis.24 We will synthesise the data into a matrix
format, structured by the messages identiﬁed in the
HPV core messages study, and allow for additional
unforeseen emerging themes (and potential new mes-
sages) to be incorporated. This approach will allow
teamwork, transparency and an audit trail of the evolu-
tion of the study ﬁndings. We will be inﬂuenced by the
‘best ﬁt framework synthesis’ used by Carroll et al25 in
integrating the synthesised interview data with the core
messages developed in previous research.
Patient interviews
Participants
We will conduct 75–90 face-to-face interviews with
patients in three phases. By recruiting participants in
two study centres (North and South Wales), we will be
able to include people from rural, semirural and urban
settings, and different socioeconomic groups, as well as
patients with different HPV-related cancer diagnoses,
male and female (where appropriate), and of varied
ages. The purposive sample aims and rationale are to
achieve an even spread of recruitment across cancer
sites, although we will not attempt to recruit patients
with penile cancer as this is a very rare condition.
Although cases of cervical cancer are most numerous,
these patients are likely to be better informed about
HPV through the cervical screening programme; poten-
tially, we have more to learn from patients with other
cancer types. Since men and women may have different
information/communication needs and preferences, we
are aiming for about two-thirds male in the cancers that
affect both genders to help redress the balance against
women with HPV-related gynaecological cancers. Finally,
we will aim for more participants in the ﬁrst two phases
of interviews because there is potential in these phases
to add to or modify the messages, whereas in the third
phase we will test the ﬁnal ‘product’.
Eligible interview participants will be adults who have
full mental capacity, are aware of their cancer diagnosis
and have been informed by their cancer clinician of its
possible connection with HPV and the fact that HPV is
sexually transmitted. Patients may be at any stage from
diagnosis through follow-up; however, those who are
medically unﬁt to participate or without mental capacity
to give informed consent will be excluded. Eligible
patients will be approached by their cancer clinician,
who will brieﬂy explain the study and give a recruitment
pack containing an invitation letter, information sheet
and reply slip. Patients will respond directly to the
research team, indicating whether they would like to
take part; written consent will be obtained at the time of
the interview.
Interviews, conducted by experienced qualitative
researchers, will last 60–90 min and will take place in
participants’ homes, university or hospital locations
according to convenience and participants’ preferences.
While the content and style of each phase of interviews
will be quite different, all will begin with some back-
ground information including a brief discussion of the
participants’ current and past relationship status, stage
in the cancer journey, when and how they ﬁrst heard
about HPV and the sources of their information. All par-
ticipants will be asked a health literacy question.26 The
plans for conducting each phase of interviews are as
follows: in each case, the methods described will be
piloted on volunteers from the North East group of the
North Wales Cancer Network Patient Forum, and
further reﬁned if necessary.
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Phase 1: Selecting and prioritising the messages
Method
Card-sorting methods used in website design27–29 will be
used to select and prioritise the most important mes-
sages for clinicians to discuss with their patients, and
identify which are of lesser importance and possibly suit-
able as take-home information. Participants will be pre-
sented with around 20 cards, each printed with a factual
statement that is either applicable to all HPV-related
cancers or to the participant’s speciﬁc cancer. The cards
will be presented in no particular order (shufﬂed) and
participants will be given time to read the messages and
select up to ﬁve that they consider to be most important.
They will be encouraged to comment on their choices,
talk through the thinking process by which they reach
their decisions, and ask questions if they are unsure of
any statement’s meaning or relevance. In collaboration
with the participant, the interviewer will use coloured
stickers to mark the participants’ choices and may also
write their (participants’) comments on the cards.
Comments may be recorded verbatim or summarised
(depending on length), and the accuracy of summarised
versions veriﬁed by the participant. Blank cards will be
supplied for any additional messages participants think
should be included, or questions they think are not
addressed. As soon as possible after the interview, the
researcher will transfer any data recorded on the cards
to a data-recording sheet, and record their own reﬂec-
tions on the interview. The interviews will be audio
recorded to aid completion of the data sheets.
Analysis
We will collate the written responses, and analysis will be
a combination of vote-counting of the messages identi-
ﬁed as most and least important, and a descriptive
content analysis of the collated comments. Content ana-
lysis is an appropriate method for “capturing and inter-
preting common-sense, substantive meanings in the
data”30; we will organise the data in a matrix and look
for themes and relationships that help to explain which
participants prioritise which messages, and why.31 The
study advisory group will meet to review and discuss the
analysed data and make a ﬁnal selection of the most
important messages. They will also discuss whether new
messages suggested by participants (if any) should be
included.
Phase 2: Phrasing and framing the messages
Method
In phase 2, a second group of participants will comment
on the language and tone of the messages. The
researcher will explain that the meaning may not be
altered (since all the messages are evidence-based);
however, the wording may be changed if necessary, for
example, to clarify the meaning, soften the tone or sim-
plify the language. The messages will be presented, one
at a time, on printed cards similar to those used in
phase 1, allowing as much time for thought and
discussion as individuals want. Audio recordings will be
made and suggested changes in wording, participants’
comments and interviewers’ reﬂections recorded on a
data sheet as before.
Analysis
Proposed changes and comments for each message will
be collated and reviewed by the study advisory group.
The group will meet and discuss the merit of proposed
changes and adjudicate between competing suggestions,
ensuring that they are framed according to the aim of
the message (informative, explanatory, reassuring, etc)
and that the underlying meanings remain intact. The
ﬁnal versions will be reached by consensus.
Phase 3: Testing the scripts
Method
We will create versions of the scripts for each cancer site.
The format will most likely be a two-sided information
sheet. On the ﬁrst side will be the information deemed
most important in the process described above, while
the second side will be framed as ‘further information’
or ‘frequently asked questions’. We will refer to the
Patient Information Forum’s online ‘Toolkit’ for guid-
ance with regard to layout and use of images, graphics,
etc,21 and we will present the scripts at a meeting of the
North Wales Cancer Patient Forum for additional feed-
back on the layout and content. In this phase, we will
test the acceptability and usefulness of the scripts
through cognitive debrief interviews and further reﬁne
them as necessary.
Page 1 of the scripts will be read with individual
patients, by a researcher, as though in a consultation. The
researcher will provide explanations and clariﬁcations as
requested by the interviewee. Then the patient will read
page 2 to him/herself, as though at home. This will be
followed by a cognitive interview to assess their under-
standing of the scripts. Cognitive interviewing allows
assessment of (1) how patients understand messages, (2)
how such messages are used to draw on relevant attitudes
and existing knowledge and (3) how this informs their
thinking.32 We will use this iterative process to identify
and modify any problem areas in the scripts. Cognitive
interviewing generally involves probing and think-aloud
techniques to assess survey item adequacy using struc-
tured interview schedules.32 33 We will adapt this method-
ology for developing information messages. Cognitive
interviews will be audio recorded for analysis.
Analysis
Analysis of the cognitive interviews will be descriptive
and focus on the attributes of the scripts and informa-
tion sheets that compromise understanding. Depending
on the actual quantity of information (messages) within
the script, interview schedules may prioritise compo-
nents thought to be less accessible to patients. Analysis
will aim to summarise observations for such messages,
but will also allow for other emergent issues elsewhere.
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Coding of interview observations will emerge from the
data set. Of particular interest will be alternate formula-
tions of messages suggested in the interview by either
the patient or the interviewer, which may inform
message revision. Results will be presented as message
level descriptive summaries of observed problems suit-
ably categorised and providing diagnostic information to
guide revision.
Outcomes
The ﬁnal product will be a family of novel tailored,
scripted consultations that are framed and contextua-
lised and ﬁeld tested on patients as offering messages
that are succinct, salient, reassuring and relevant. Each
scripted consultation will comprise key information
phrased in plain language for the clinician to use in
their consultation, accompanied by further information
for the patient to read, the whole to be printed on one
sheet of paper for the patient to take home. The mes-
sages will be readily adaptable to other formats and pur-
poses such as web-based educational materials for
clinicians and informational materials for patients.
DISCUSSION
The main challenge for this study is that there is no
‘standard’ methodology for this type of work. We have
taken a pragmatic approach and adapted methods from
other contexts (card-sorting from website design, cogni-
tive interviewing from survey design), which may require
further modiﬁcation as the study progresses. However, we
consider the innovative study design to be one of its
strengths. Another is that all the messages will be based
on at least two sources of evidence, supporting the accur-
acy of the statements and the need for the information.
As well as having a patient representative on our advisory
group and involving members of the North Wales Cancer
Network Patient Forum, the participants in the study will
be actively involved in co-producing the scripts, further
ensuring their usefulness and appropriateness.
In a study to develop materials to promote informed
choice in the context of breast cancer screening, ten-
sions were reported between the professional experts
and the women taking part in the study.34 There was dis-
agreement over the appropriate level of detail, particu-
larly where the science is uncertain, and the
communication of quantitative information. In our
study, we see the sensitivity of the information as the key
problem, and here the patient perspective is paramount;
we have much less focus on the communication of quan-
titative information and risk. However, if tensions do
arise between the patient and professional perspectives,
we will consider testing alternative versions of the scripts
in the phase three cognitive debrief interviews.
The interviews will focus on the information we are
developing rather than experiences of individual partici-
pants, though experiences will no doubt inform indivi-
duals’ responses. In keeping with a non-judgemental
attitude and the approach that all sexually active adults are
susceptible to HPV infection, we will avoid asking ques-
tions about individuals’ sexual orientation or behaviour.
Therefore, we will be unable to stratify by sexual orienta-
tion, and there is likely to be some bias towards heterosex-
uals in the samples. However, if any participants identify
themselves as lesbian, gay, bisexual or transgender, we will
explore that perspective and endeavour to ensure a range
of participants in terms of age, gender, socioeconomic
status, cancer site and health literacy. Owing to their rarity,
we decided not to recruit patients with penile cancer, but
we anticipate that their needs for information about HPV
will not be dissimilar from patients with other HPV-related
cancers and we will look for differences between groups
that might shed light on this issue.
The resulting scripts should be generalisable beyond
the UK NHS setting, as these difﬁcult conversations
about HPV-related cancers are based on global literature
and will be easy to modify for other settings. Our inten-
tion is to evaluate this approach in terms of effectiveness
and cost-effectiveness of this approach in a future prag-
matic randomised trial.
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